Structure Therapeutics

We're pleased to announce positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with #obesity and/or overweight with at least one weight related co-morbidity. This includes 44-week data from the Phase 2 ACCESS II study and interim data from the ongoing body composition study and the ACCESS open label extension study. Read more: ir.structuretx.com/news-releases/…

Today, we reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. Top highlights include: 📊Topline 44-week data from ACCESS II study with higher doses expected in Q1 2026; ▶️Aleniglipron Phase 3 initiation expected in 2H 2026; 📈Initial data from Phase 1 study of oral small molecule amylin receptor agonist ACCG-2671 and Phase 1 initiation of second oral #amylin compound ACCG-3535 expected in 2H 2026. Read the full announcement: ir.structuretx.com/news-releases/…

We are heartbroken by the tragic passing of our dear colleague and friend. She was a remarkable leader, trusted voice and deeply valued teammate. Her impact on our organization and the lives of those around her will not be forgotten.

We’ve initiated our first-in-human Phase 1 clinical study of ACCG-2671, our lead oral #smallmolecule amylin receptor agonist for the treatment of #obesity. Read more here: ir.structuretx.com/news-releases/…

We're excited to announce positive topline data from the ACCESS clinical program of aleniglipron, an orally-available, once-daily, nonpeptide small molecule agonist of the #GLP1 receptor, for the treatment of people living with #obesity and/or overweight with at least one weight-related comorbidity. These findings provide comprehensive information to move into Phase 3 development and reinforce aleniglipron’s potential to become a backbone oral small molecule therapy for obesity—one that is accessible, scalable, and combinable. Read more: ir.structuretx.com/news-releases/…

Our team members in Shanghai joined in the spirit of friendly competition at the Shanghai J.P. Morgan Corporate Challenge! Following our U.S. team’s debut at the San Francisco event earlier this year, our Shanghai colleagues took to the course to continue the celebration of teamwork, wellness, and community that defines Structure. It was a day filled with energy and connection, reminding us that no matter where we are in the world, we’re all part of the same team striving toward shared goals. #JPMCC

It was an honor to host patient advocates and @ObesityAction board members Jason Krynicki and Michele Tedder at our U.S. office to share their experiences and perspectives on the importance of access to care, addressing weight bias and its impact on mental health, and ensuring fair representation for people living with #obesity. Their stories and tireless advocacy remind us why continued dialogue, understanding, and innovation are essential to improving care for those living with obesity. We’re deeply grateful for their time and openness.

In recognition of both #WorldDiabetesDay and #AmericanDiabetesMonth, our teams across the U.S. and Shanghai came together to raise awareness and promote healthy living. From wear blue days and wellness walks to Tai Chi, nutrition-focused lunch and learns, our team members connected through movement, mindfulness, and education. We extend our special thanks to Athena Philis-Tsimikas, M.D., a specialist in endocrinology, diabetes, and metabolism, for sharing her valuable insights on diabetes health with us. These moments not only strengthened our commitment to supporting those affected by #diabetes, but also reminded us of the importance of balance, access, and care in everyday life.

On #WorldDiabetesDay, we recognize the global impact of diabetes and the need for accessible, effective treatments. Explore this year’s theme, “Diabetes and the Workplace”, and how equitable access to care can make a difference: worlddiabetesday.org

We had a great time connecting with the community at the @ObesitySociety's @ObesityWeek. It was inspiring to join clinicians, researchers, advocacy, and industry partners who are committed to advancing science and improving care for people living with #obesity and #metabolicdiseases. Conversations like these reinforce the importance of developing accessible, scalable medicines that can make a meaningful difference for patients worldwide. #OW2025

Today, we reported financial results for Q3 2025 and provided a business update. Top highlights include: ➡️ Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025; ➡️ Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study initiation anticipated by year-end 2025; ➡️ Second oral amylin receptor agonist (ACCG-3535) development candidate selected Read more: ir.structuretx.com/news-releases/…

Proud to support the #obesity community in the 2025 @ObesityAction 20 Million Step Challenge! Our team logged 4.8M+ steps, helping reach a total of 26M steps to raise awareness and funds for OAC’s mission. Learn more about the organization here: obesityaction.org

On #WorldHeartDay, we recognize the importance of raising awareness around heart health and its risk factors. Obesity remains a leading contributor to cardiovascular disease and other conditions that can significantly impact overall well-being. At Structure, it's our mission is to make medicines broadly accessible for people living with chronic disease indications such as #obesity.

Team Structure hit the pavement for the San Francisco J.P. Morgan Corporate Challenge! It was our first time participating in the San Francisco event, and it was a great reminder that teamwork extends beyond the workplace. We loved the chance to connect outside the office, challenge ourselves, and celebrate community together. #JPMCC

We were honored to team up with @SFUnified to help local students get ready for the new school year. Through this effort, our team helped provide 200 students with essential school supplies they need to thrive in the classroom. It’s a small gesture with a big impact, and we’re proud of our team for showing up with such generosity and heart. Here’s to giving every student the tools they need to start strong! Learn more about the organization here: ssfusd.org

Today, we reported financial results for the second quarter ended June 30, 2025, and provided a business update. Top highlights include: ➡️ Topline data from oral small molecule GLP-1 RA aleniglipron Phase 2b ACCESS and ACCESS II studies on track for year-end 2025 readouts ➡️ Aleniglipron clinical development program expanded to optimize competitive positioning and Phase 3 program ➡️ Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025 Read the full announcement: ir.structuretx.com/news-releases/…

Today on #NationalInternDay, we're celebrating the incredible contributions of our interns in both South San Francisco and Shanghai as part of Structure’s Global Internship Program. This program is designed to give students meaningful, hands-on experience applying their studies to real-world challenges in #biotech. We're proud to invest in the next generation of leaders and are grateful for the energy, adaptability, and enthusiasm they bring to Structure.

We were proud to attend the @ObesityAction's Your Weight Matters Convention, an inspiring event including patients, advocates, clinicians, and organizations all working toward a healthier, more inclusive future for individuals living with #obesity. Being part of this event reminded us of the power of community and the importance of listening to the lived experiences of those most impacted. We remain committed to advancing science that supports and uplifts the obesity community. #YWM2025

We’re back from an inspiring few days at #ADASciSessions, where the energy around innovation in the obesity field was truly remarkable. It was a milestone moment for Structure as we debuted our first-ever medical booth and shared exciting preclinical data from our oral #smallmolecule programs. Just as importantly, we had the chance to connect with many community and industry leaders, researchers, and clinicians who share our commitment to expanding access and advancing care for people living with #obesity.